Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group

British Journal of Haematology
S LenhoffNordic Myeloma Study Group

Abstract

The value of intensive therapy, including autologous stem cell transplantation, in newly diagnosed myeloma patients >60 years is not clear. We evaluated the impact of age (<60 years vs. 60-64 years) on survival in a prospective, population-based setting and compared survival with conventionally treated historic controls. The prospective population comprised 452 patients registered between 1998 and 2000. Of these, 414 received intensive therapy. The historic population, derived from our most recent population-based study on conventional therapy, comprised 281 patients. Of these, 243 fulfilled our eligibility criteria for intensive therapy. For patients undergoing intensive therapy it was found that two factors, beta-2-microglobulin and age <60 years vs. 60-64 years, had independent prognostic impact on survival. However, compared with the historic controls a survival advantage was found both for patients <60 (median 66 months vs. 43 months, P < 0.001) and 60-64 years (median 50 months vs. 27 months; P = 0.001). We conclude that in a population-based setting higher age adversely influences outcome after intensive therapy. Our results indicate that intensive therapy prolongs survival also at age 60-64 years but with less superiori...Continue Reading

References

Oct 16, 1999·British Journal of Haematology·I TuressonF Wislöff
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
May 17, 2003·Leukemia·A GratwohlUNKNOWN Lymphoma Working Party
Dec 4, 2003·Bone Marrow Transplantation·D E ReeceD H Vesole
Nov 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Paul FermandUNKNOWN Group Myelome-Autogreffe

❮ Previous
Next ❯

Citations

Sep 16, 2008·Clinical and Experimental Medicine·Francesca MerchionneFranco Dammacco
Aug 25, 2007·Nature Reviews. Molecular Cell Biology·Norman E Sharpless, Ronald A DePinho
Dec 17, 2009·The Cancer Journal·Sigurdur Yngvi KristinssonVincent S Rajkumar
Apr 9, 2011·Case Reports in Oncology·Soo-Young BaeJe-Jung Lee
Apr 25, 2007·Leukemia & Lymphoma·Federica CavalloAntonio Palumbo
Jan 13, 2015·Leukemia & Lymphoma·Anne K MylinUNKNOWN Nordic Myeloma Study Group
Feb 25, 2009·Expert Opinion on Pharmacotherapy·Selmin A AtaerginHillard M Lazarus
Aug 24, 2007·Expert Opinion on Investigational Drugs·Pellegrino Musto, Fiorella D'Auria
Nov 30, 2006·International Journal of Cancer. Journal International Du Cancer·Annette VangstedUlla Vogel
Sep 3, 2011·European Journal of Haematology·Annette VangstedUlla Vogel
Jun 10, 2010·Cytometry. Part B, Clinical Cytometry·Hans E JohnsenUNKNOWN Myeloma Stem Cell Network (MSCNET)
Dec 6, 2011·International Journal of Cancer. Journal International Du Cancer·Niels F AndersenAnnette J Vangsted
Jun 24, 2014·European Journal of Haematology·Niels F AndersenAnnette J Vangsted
May 31, 2015·Drugs & Aging·Erica L CampagnaroHillard M Lazarus
May 12, 2015·Bone Marrow Transplantation·T M WildesG Colditz
Apr 5, 2011·Hematology/oncology and Stem Cell Therapy·Jean El CheikhDidier Blaise
Apr 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sigurdur Yngvi KristinssonMagnus Björkholm
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tanya M WildesSascha A Tuchman
Feb 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz LudwigBrian Durie
Aug 30, 2017·Leukemia & Lymphoma·Evan DiamondHeather Landau
Nov 9, 2016·World Journal of Stem Cells·Maximilian StahlAmer M Zeidan
Jun 20, 2020·European Journal of Haematology·Fredrik Schjesvold
Dec 21, 2017·Expert Review of Hematology·Hussein G Elsayed, Amal S Alabdulwahab
Nov 27, 2019·Annals of Hematology·Sho OkamotoShinya Kimura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.